Vascular Inflammation in Psoriasis Trial (The VIP Trial) (VIP)
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
Sponsor: University of Pennsylvania
This PHASE4 trial investigates Cardiovascular Disease and Psoriasis and is currently completed. University of Pennsylvania leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .